arrow
M

Mary W. Redman

Fred Hutch Cancer Center
H指数:44
被引数:7,377

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia

靶向CD20的自体CAR T细胞疗法治疗华氏巨球蛋白血症

Blood
IF23.1
2026-01-010
OAAI
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial

新辅助帕博利珠单抗联合加速甲氨蝶呤、长春碱、多柔比星和顺铂在非尿路上皮性肌层浸润性膀胱癌不同组织学亚型中的应用:一项II期临床试验

2025-08-050
PRE
S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

S1701,卡铂-紫杉醇联合或不联合雷莫芦单抗治疗局部晚期、复发或转移性胸腺癌患者的随机2期试验

2024-12-010
OA
B7-H3 is widely expressed in soft tissue sarcomas
2024-10-302
OAAI
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
2024-01-265
OAAI
Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2023-06-091
PRE
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I
2023-01-106
PRE
Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer

III期非小细胞肺癌预防性颅脑照射的成本效益

2022-05-012
OAAI
Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials
2021-11-010
OAAI
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)
2021-07-0121
OAAI
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Teisotuzumab Vedotin在c-met阳性IV期或复发性鳞状细胞肺癌患者中的II期研究 (Lung-MAP子研究S1400K,NCT03574753)

2021-05-0153
OAAI
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

SWOG S1400A (NCT02154490): Durvalumab用于先前治疗过IV期或复发性鳞状细胞肺癌患者的II期研究 (Lung-MAP子研究)

2021-05-015
OAAI
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
2021-05-0121
OAAI